Effect of Genistein on the Transgenic Drosophila Model of Parkinson's Disease

J Diet Suppl. 2019;16(5):550-563. doi: 10.1080/19390211.2018.1472706. Epub 2018 Jul 3.

Abstract

Parkinson's disease (PD) is the second-most common neurodegenerative disorder and is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta. Oxidative stress has also been linked with the progression of PD, hence the involvement of a natural plant product could offer neuroprotection. The present study deals with the effect of genistein on the transgenic flies expressing normal human alpha synuclein panneurally. The PD flies were exposed to 10, 20, 30, and 40 µM of genistein (mixed in diet) for 24 days. A significant dose-dependent increase in the life span and delay in the loss of climbing ability were observed in the PD flies exposed to genistein (p < .05). A significant dose-dependent decrease in oxidative stress markers and increase in dopamine content were observed in PD flies exposed to genistein. However, the exposure of genistein did not inhibit the expression of α-synuclein in the brains of PD flies.

Keywords: Parkinson's disease; alpha synuclein; flavonoids; genistein; oxidative stress.

MeSH terms

  • Animals
  • Animals, Genetically Modified*
  • Brain / drug effects
  • Brain / metabolism
  • Disease Models, Animal
  • Dopamine / analysis
  • Drosophila* / genetics
  • Drosophila* / metabolism
  • Gene Expression
  • Genistein / therapeutic use*
  • Humans
  • Locomotion / drug effects
  • Monoamine Oxidase / metabolism
  • Neurons / metabolism
  • Parkinson Disease / drug therapy*
  • alpha-Synuclein / genetics

Substances

  • SNCA protein, human
  • alpha-Synuclein
  • Genistein
  • Monoamine Oxidase
  • Dopamine